Kanagawa, Japan

Ryo Mizojiri


 

Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Osaka, JP (2014)
  • Fujisawa, JP (2017)
  • Kanagawa, JP (2015 - 2023)

Company Filing History:


Years Active: 2014-2025

where 'Filed Patents' based on already Granted Patents

7 patents (USPTO):

Title: Ryo Mizojiri: Innovator in Cancer Therapeutics

Introduction

Ryo Mizojiri is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target cancer treatment. With a total of seven patents to his name, Mizojiri is recognized for his innovative approaches to drug discovery.

Latest Patents

Mizojiri's latest patents include groundbreaking work on nitrogen-containing heterocycles as CDK12 inhibitors. These compounds are designed to exhibit superior CDK12 inhibitory action, making them promising candidates for prophylactic or therapeutic drugs against cancer and similar diseases. The compounds are represented by specific formulas, with each symbol defined in the detailed descriptions of the patents.

Career Highlights

Mizojiri is currently employed at Takeda Pharmaceutical Company Limited, where he continues to advance his research in oncology. His work has been instrumental in developing new therapeutic strategies that could potentially improve patient outcomes in cancer treatment.

Collaborations

Throughout his career, Mizojiri has collaborated with notable colleagues, including Moriteru Asano and Hironobu Maezaki. These partnerships have fostered a collaborative environment that enhances the innovation process within the pharmaceutical industry.

Conclusion

Ryo Mizojiri stands out as a key figure in the realm of cancer therapeutics, with a strong portfolio of patents that reflect his dedication to improving healthcare. His contributions are expected to have a lasting impact on the treatment of cancer and related conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…